Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 47

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2017

Summary

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2017, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene. The molecules developed by companies in Phase II and Preclinical stages are 2 and 4 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Ophthalmology which include indications Amyotrophic Lateral Sclerosis, Parkinson's Disease, Brain Ischemia, Neurodegenerative Diseases and Retinal Degeneration.

Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects

- The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview 6
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development 20
GlaxoSmithKline Plc 20
Treeway BV 20
UniQure NV 20
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles 22
AMT-090 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Drugs for Neurodegenerative Diseases - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
GSK-812 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
LAUR-301 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
smilagenin - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Stem Cell Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TW-002 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products 34
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones 35
Featured News & Press Releases 35
Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients 35
Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association 36
Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy 37
Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane 37
Feb 18, 2013: Phytopharm Announces Results From Parkinson's Disease Clinical Trial Of Cogane 38
Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis 39
Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson's Disease 40
Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis 40
Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study 41
Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis 42
Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status 43
Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease 43
Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane 44
Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson's Disease 44
Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by GlaxoSmithKline Plc, H2 2017 20
Pipeline by Treeway BV, H2 2017 20
Pipeline by UniQure NV, H2 2017 21
Dormant Projects, H2 2017 34

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18
  • Global Pyrogen Testing Detailed Analysis Report 2017-2022
    Published: 19-Sep-2017        Price: US 3250 Onwards        Pages: 107
    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Pyrogen Testing industry. This report splits Pyrogen Testing market By Product, By Test, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022. This report focuses Global market, it covers details a......
  • Global and Europe Pyrogen Testing Market - Analysis and Outlook to 2022
    Published: 19-Sep-2017        Price: US 2960 Onwards        Pages: 110
    This report presents a comprehensive overview of the Pyrogen Testing market in Europe, which shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. This report provides a detailed analysis of the market, including its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Pyrogen Testing industry. This report focuses Global......
  • 2017-2022 Global and Japan Pyrogen Testing Market Analysis Report
    Published: 19-Sep-2017        Price: US 3085 Onwards        Pages: 102
    The global Pyrogen Testing market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022. Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%. This report, with focus on top players in the global and Japan, studies the Pyrogen Testing market's development status and future trend in the g......
  • Global Ion Indicators Market Research Report 2017
    Published: 18-Sep-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Ion Indicators market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Ion Indicators in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Global Ion Indicators Sales Market Report 2017
    Published: 18-Sep-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Ion Indicators market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Ion Indicators for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan ......
  • Global Mice Model Market Research Report 2017
    Published: 18-Sep-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Mice Model market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Mice Model in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan ......
  • Global Cytokines Market Research Report 2017
    Published: 15-Sep-2017        Price: US 2900 Onwards        Pages: 116
    In this report, the global Cytokines market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cytokines in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - ......
  • Global Microbial Products Sales Market Report 2017
    Published: 15-Sep-2017        Price: US 4000 Onwards        Pages: 110
    In this report, the global Microbial Products market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Microbial Products for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan......
  • Global Antibody Engineering Services Market Size, Status and Forecast 2022
    Published: 14-Sep-2017        Price: US 3300 Onwards        Pages: 131
    This report studies the Antibody Engineering Services market status and outlook of global and major regions, from angles of players, regions, product and end Application/industries; this report analyzes the top players in global and major regions, and splits the Antibody Engineering Services market by product and Application/end industries. The global Antibody Engineering Services market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs